The schematic diagram of this molecular regulation is delineated in Fig. 6, suggesting that the therapeutic effect of ATO on NSCLC cells, in which P62, upon ATO binding, might undergo conformational changes that enable an enhanced interaction with the EGFR L858R/T790M mutant and in turn lead to an autophagy-based EGFR degradation (Fig. 4g). Here, SQSTM1 is linked to non-small cell lung carcinoma.